Aduro inks agreement with Janssen Biotech for prostate cancer candidates
Aduro BioTech, a clinical-stage biotechnology company, has entered into an agreement granting Janssen Biotechan exclusive worldwide license to certain product candidates specifically engineered for the treatment of prostate cancer based on its novel LADD immunotherapy platform. The agreement is facilitated by the Johnson & Johnson Innovation center in California. Aduro is eligible to receive up to $365 million in upfront license fees and milestone payments upon achievement of defined development, regulatory and commercialization milestones, if multiple programs advance to commercialization, as well as tiered royalties on worldwide net sales.
Janssen will assume responsibility for all research, development, manufacturing, regulatory and commercialization activities for the licensed products. Under a separate agreement, Aduro has granted Janssen exclusive rights to Aduro's GVAX technology for prostate cancer.